Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (431-440 of 1,211) with videos related to

Pageof 122
Sort By:
European Heart Journal|November 27, 2020
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled studyJörg Täubel, Wilfried Hauke, Steffen Rump, et al.
JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.
Journal of the American College of Cardiology|April 15, 2014
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseJacob A Udell, David A Morrow, Petr Jarolim, et al.
Circulation. Heart Failure|February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist TrialCarine E Hamo, John F Heitner, Marc A Pfeffer, et al.
European Heart Journal|May 26, 2011
Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trialAnne-Catherine Pouleur, Dorit Knappe, Amil M Shah, et al.
European Journal of Heart Failure|October 23, 2010
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarctionAmil M Shah, Hajime Uno, Lars Køber, et al.
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudyGary F Mitchell, Mark E Dunlap, Wayne Warnica, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JACC. Heart Failure|February 10, 2020
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
Pageof 122

Showing results (431-440 of 1,211) with videos related to

Sort By:
Pageof 122
European Heart Journal|November 27, 2020
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled studyJörg Täubel, Wilfried Hauke, Steffen Rump, et al.
JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.
Journal of the American College of Cardiology|April 15, 2014
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseJacob A Udell, David A Morrow, Petr Jarolim, et al.
Circulation. Heart Failure|February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist TrialCarine E Hamo, John F Heitner, Marc A Pfeffer, et al.
European Heart Journal|May 26, 2011
Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trialAnne-Catherine Pouleur, Dorit Knappe, Amil M Shah, et al.
European Journal of Heart Failure|October 23, 2010
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarctionAmil M Shah, Hajime Uno, Lars Køber, et al.
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudyGary F Mitchell, Mark E Dunlap, Wayne Warnica, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JACC. Heart Failure|February 10, 2020
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
Pageof 122